Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2025
Reporting Period: Events occurring on August 13, 2025, with transactions closing on August 14, 2025.
Context: The Company, an emerging growth company, executed a private placement of Series B Convertible Preferred Stock and warrants, a warrant inducement transaction, and amendments to existing warrants to reclassify liabilities to equity.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: Expected gross proceeds of approximately $1.2 million from the sale of 990 shares of Series B Convertible Preferred Stock and associated warrants.
- Warrant Inducement Proceeds: Gross proceeds of $253,000 from the cash exercise of existing warrants at a reduced price.
- Equity Reclassification: Amendments to May 2025 Warrants are expected to increase stockholders' equity by approximately $2.8 million by reclassifying liabilities.
- Authorized Capital: Common stock authorized shares increased from 100,000,000 to 350,000,000.
- Transaction Costs: Placement agent fees of 7.5% of aggregate purchase prices; expense reimbursements capped at $65,000 (Private Placement) and $15,000 (Inducement).
Material Changes and Transactions
Private Placement Transaction
The Company sold 990 shares of Series B Convertible Preferred Stock (Stated Value $1,000/share) and warrants to purchase 6,714,780 shares of Common Stock.
- Conversion Terms: Initial conversion price of $0.23 per share, yielding 4,304,343 Conversion Shares.
- Warrant Terms: Exercise price of $0.352 per share.
- Use of Proceeds: Working capital and general corporate purposes.
Warrant Inducement Transaction
The Company induced the exercise of 1,100,000 existing warrants (originally priced at $1.25 and $1.50) by reducing the exercise price to $0.23 per share.
- Inducement: Issuance of 1,430,000 new warrants (exercise price $0.352) contingent on stockholder approval for issuances exceeding 19.99% of outstanding shares.
- Closing: August 14, 2025.
Warrant Amendment and Anti-Dilution Adjustment
May 2025 Warrants were amended to remove liability treatment provisions. Additionally, anti-dilution provisions triggered by the Private Placement adjusted the exercise price to $0.23 and increased the number of issuable shares by approximately 8 million.
Guidance, Outlook, and Risks
- Registration Rights: The Company must file registration statements for the resale of Conversion Shares and New Warrants within 15 days of the agreements, with effectiveness targeted within 60 days (or 90 days if a full SEC review occurs).
- Stockholder Approval: Issuance of shares underlying the New Warrants and Series B Preferred Stock exceeding 19.99% of outstanding shares requires stockholder approval.
- Conversion Limitations: Holders of Series B Preferred Stock are limited to converting shares such that they do not beneficially own more than 4.99% of outstanding Common Stock without further approval.
- Anti-Dilution Floor: The Series B Preferred Stock conversion price has a floor of $0.10 per share.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7.5% placement agent fees and estimated offering expenses.
- Confirm the timeline for the effectiveness of the registration statements for the resale of Conversion Shares and New Warrants.
- Monitor the status of the required stockholder approval for issuances exceeding the 19.99% threshold.
- Review the impact of the $2.8 million equity reclassification on the Company's balance sheet in the next quarterly report.
- Assess the dilution impact of the 8 million share increase in the May 2025 Warrants and the 6.7 million shares underlying the new Private Placement warrants.